NCT04138875 2022-06-23A Risk Stratified Sequential Treatment With Rituximab, Brentuximab Vedotin and Bendamustine (RBvB)Yale UniversityPhase 2 Withdrawn
NCT00430534 2007-02-02Evaluation of Safety, Immune-Response and Efficacy of GSK Biologicals' EBV (Epstein Barr Virus) Vaccine (268664).HenogenPhase 2 Completed200 enrolled